Drug Trial Radar · NCT05781750
A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)
Last checked: Nov 20, 2026Latest source record: Dec 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
84
Actual
Start
Nov 3, 2023
Primary completion
Nov 8, 2024
Study completion Nov 8, 2024
Sponsor
- Lead sponsor
- Kezar Life Sciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to assess the efficacy and safety of zetomipzomib (30 mg or 60 mg) compared with placebo in achieving renal response after 52 weeks of treatment in patients with active lupus nephritis (LN).
Conditions
- Lupus Nephritis
Interventions
zetomipzomibDrug
Subcutaneous injection of zetomipzomib
placeboDrug
Subcutaneous injection of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Patients Achieving Complete Renal ResponseTime frame: Week 37
Locations
50 sites in 12 countries. Site status is shown where the registry gives one.
Accurate Clinical Research - Lake Charles
Lake Charles, Louisiana
Nephrology Associates, Inc
East Providence, Rhode Island
Precision Comprehensive Clinical Research Solutions
Colleyville, Texas
Prolato Clinical Research Center (PCRC)
Houston, Texas
Framingham Medical Center
Buenos Aires, Argentina
Medical Research Organization
Buenos Aires, Argentina
Aprillus Assistance and Research by Arcis Health
Buenos Aires, Argentina
Dr. Doreski Medical Offices
Buenos Aires, Argentina
Military Central Hospital
Buenos Aires, Argentina
Austral University Hospital
Pilar, Argentina
Mayo Clinic of UCMB SRL
San Miguel de Tucumán, Tucumán Province, Argentina
Clinical Hospital FMUSP
São Paulo, Brazil
Holy House of Mercy of Belo Horizonte
Belo Horizonte, Minas Gerais, Brazil
Clinics Hospital FMRP
Ribeirão Preto, São Paulo, Brazil
Faculty of Medicine of SJRP
São José do Rio Preto, São Paulo, Brazil
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Costa Clinica
Barranquilla, Atlántico, Colombia
Laiko General Hospital of Athens
Athens, Greece
Center for Advanced Health Clinical Studies
Guatemala City, Guatemala
Clinical Research Center, S.A.
Guatemala City, Guatemala
Medical Clinic Specialized in Internal Medicine and Rheumatology
Guatemala City, Guatemala
Medical Clinic Specialized in Internal Medicine and Rheumatology
Guatemala City, Guatemala
All India Institute of Medical Sciences
Raipur, Chhattisgarh, India
Nirmal Hospital
Surat, Guajrat, India
Unity Hospital
Surat, Guajrat, India
Panchshil Hospital
Ahmedabad, Gujarat, India
Elite Mission Hospital
Thrissur, Kerala, India
MGM Medical College and Hospital
Chhatrapati Sambhajinagar, Maharashtra, India
Kingsway Hospital
Nagpur, Maharashtra, India
Jasleen Hospital
Nagpur, Maharashtra, India
Assured Care Plus Hospital
Nashik, Maharashtra, India
Sir Ganga Ram Hospital
New Delhi, NCT of Delhi, India
SMS Medical College
Jaipur, Rajasthan, India
Yashoda Hospitals
Hyderabad, Telangana, India
Krishna Institute of Medical Science
Secunderabad, Telangana, India
University Malaya Medical Centre
Kuala Lumpur, Malaysia
Prince Court Medical Centre
Kuala Lumpur, Kuala Lumpur, Malaysia
Hospital Raja Permaisuri Bainun
Ipoh, Perak, Malaysia
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.